Global Atrial Flutter Market, By Type (Typical Atrial Flutter, Atypical Atrial Flutter, Left Atrial Flutter, Reverse Typical Atrial Flutter, Incisional Atrial Re-entry), Treatment (Antiarrhythmics, Beta-blockers, Anticoagulants, Cardioversion, Catheter ablation, Surgery, Others), Diagnosis (Holter monitoring, Blood Tests, Electrocardiography (ECG), Event monitoring, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), Symptoms (Fatigue, Chest pain, Shortness of breath, Palpitations, Pre-syncope, Blurry vision, Light headedness, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.
Atrial Flutter Market Analysis and Size
Atrial flutter is a common cardiac arrhythmia, especially among the elderly population. As the global population ages, there is a higher prevalence of atrial flutter cases, driving the demand for diagnosis, treatment, and management options. Technological advancements in electrocardiography (ECG), echocardiography, and other diagnostic tools have improved the accuracy and efficiency of atrial flutter diagnosis. Early and accurate diagnosis can lead to timely treatment, driving market growth. Pharmaceutical companies and medical device manufacturers are continually developing new treatment options and therapies for atrial flutter. These innovations include medications, catheter ablation procedures, and implantable devices like pacemakers and implantable cardioverter-defibrillators (ICDs).
Data Bridge Market Research analyses that the global atrial flutter market which was USD 14,530.00 million in 2022, is expected to reach USD 36,233.52 million by 2030, and is expected to undergo a CAGR of 12.1% during the forecast period of 2023 to 2030. “Typical atrial flutter” dominates the type segment of the global atrial flutter market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Atrial Flutter Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Typical Atrial Flutter, Atypical Atrial Flutter, Left Atrial Flutter, Reverse Typical Atrial Flutter, Incisional Atrial Re-entry), Treatment (Antiarrhythmics, Beta-blockers, Anticoagulants, Cardioversion, Catheter ablation, Surgery, Others), Diagnosis (Holter monitoring, Blood Tests, Electrocardiography (ECG), Event monitoring, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), Symptoms (Fatigue, Chest pain, Shortness of breath, Palpitations, Pre-syncope, Blurry vision, Light headedness, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Medtronic (Ireland), Johnson & Johnson Sevices, Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Bristol-Myers Squibb Company (U.S.), Abbott (U.S.), Sanofi (France), Novartis AG (Switzeland), Merck Sharp & Dohme Corp. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Teva Pharmaceutical Industries Ltd.(U.K.), Baxter (Germany), Aspen Holdings (South Africa), DAIICHI SANKYO COMPANY, LIMITED (Japan), Genentech, Inc. (U.S.), Lupin (India), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Ltd. (India), and Amneal Pharmaceuticals LLC. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Atrial flutter is a type of cardiac arrhythmia (abnormal heart rhythm) that affects the atria, the upper chambers of the heart. It is characterized by a rapid and regular electrical activity in the atria, causing them to beat at a faster rate than the ventricles (the lower chambers of the heart). This can result in inefficient pumping of blood, leading to symptoms such as palpitations, shortness of breath, dizziness, and fatigue. Atrial flutter is considered a serious medical condition and may require treatment, which can include medications to control heart rate or rhythm, electrical cardioversion, or catheter-based procedures such as ablation.
The term "Global Atrial Flutter Market" refers to the market for products and services related to the diagnosis, treatment, and management of atrial flutter on a worldwide scale. This market encompasses various healthcare sectors and industries that contribute to the care of patients with atrial flutter.
Global Atrial Flutter Market Dynamics
Drivers
- Increasing Prevalence of Atrial Flutter
Atrial flutter is a common cardiac arrhythmia, especially among the elderly population. With the global aging population and the rise in risk factors such as obesity and hypertension, there may be a higher prevalence of atrial flutter cases, driving the demand for treatments and management options.
- Rising Government Initiatives
Government policies and initiatives aimed at improving cardiac care and reducing the burden of cardiovascular diseases can stimulate market growth. This may include funding for research, awareness campaigns, and improved healthcare infrastructure.
Opportunities
- Advancements in Medical Technology
The development of new medical devices, drugs, and treatment options for atrial flutter can expand the global market. Innovations in cardiac rhythm management devices, ablation techniques, and pharmaceuticals can improve patient outcomes and reduce the burden of the disease.
-
Collaboration and Mergers
Furthermore, the rising collaboration, merger, and acquisition among the market players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. In addition, rising number of market players will further expand the market's growth rate in the future.
Restraints/Challenges
- Regulatory Hurdles
Regulatory approvals for new medical devices and pharmaceuticals can be a lengthy and costly process. Companies operating in this market may face challenges in getting their products approved for use.
-
High Cost associated in Manufacturing
On the other hand, the high cost associated with the product manufacturing is expected to obstruct market growth. Also, the disruption in the supply chain industry has the potential to challenge the market’s growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, and lack of suitable infrastructure are projected to challenge the market in the forecast period of 2023-2030.
This global atrial flutter market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global atrial flutter market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- On March 2023, the University of California, San Francisco announced a study of clinical trials for Baylis Versacross RF wire. This study is a randomized controlled trial that investigates the comparative effectiveness of Baylis's Versacross RF wire and the conventional Baylis RF needle in puncturing through a thin wall in the heart, known as "transseptal puncture," during cardiac ablation procedures. The primary outcome measure is the time taken to achieve a successful transseptal puncture
- On March 2023, R-Pharm announced a study of clinical trials for Refralon. The objective of this retrospective registry is to assess the effectiveness and safety of Refralon, a concentrated solution for intravenous injection, for chemical cardioversion in routine clinical practice among patients with paroxysmal and persistent atrial fibrillation and flutter
- On April 2023, NeuTrace Inc announced a study of clinical trials for Electroanatomic mapping with the NeuTrace System. The trial aims to assess physician acceptance of the NeuTrace System v1.0 for cardiac electroanatomic mapping through a prospective, non-randomized, single-arm feasibility trial
Global Atrial Flutter Market Scope
The global atrial flutter market is segmented on the basis of type, treatment, diagnosis, dosage, route of administration, symptoms, end-users and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Typical Atrial Flutter
- Atypical Atrial Flutter
- Left Atrial Flutter
- Reverse Typical Atrial Flutter
- Incisional Atrial Re-entry
Treatment
- Antiarrhythmics
- Beta-blockers
- Anticoagulants
- Cardioversion
- Catheter ablation
- Surgery
- Others
Diagnosis
- Holter monitoring
- Blood Tests
- Electrocardiography (ECG)
- Event monitoring
- Others
Dosage
- Tablet
- Injection
- Others
Route of Administration
- Oral
- Intravenous
- Others
Symptoms
- Fatigue
- Chest Pain
- Shortness of Breath
- Palpitations
- Pre-Syncope
- Blurry Vision
- Light Headedness
- Others
End Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Atrial Flutter Market Regional Analysis/Insights
Global atrial flutter market is analyzed, and market size insights and trends are provided by type, treatment, diagnosis, dosage, route of administration, symptoms, end-users and distribution channel as referenced above.
The countries covered in the global atrial flutter market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
North America dominates the global atrial flutter market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2023 to 2030. This is due to the presence of FDA approved wound debridement devices and rising healthcare expenditure will further propel the market's growth rate in this region. In addition, favourable health remuneration policies, rise in chronic wounds, and a growing elderly population will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest growing region in the global atrial flutter market during the forecast period of 2022-2029 due to increase in the number of insurance payers in this region. Also, the development of private healthcare sector and rising awareness among the people will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global atrial flutter market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global atrial flutter market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global atrial flutter market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Atrial Flutter Market Share Analysis
The global atrial flutter market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global atrial flutter market.
Some of the major players operating in the global atrial flutter market are:
- Medtronic (Ireland)
- Johnson & Johnson Services, Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Bristol-Myers Squibb Company (U.S.)
- Abbott (U.S.)
- Sanofi (France)
- Novartis AG (Switzeland)
- Merck Sharp & Dohme Corp. (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Eli Lilly and Company (U.S.)
- AstraZeneca (U.K.)
- Bayer AG (Germany)
- Teva Pharmaceutical Industries Ltd. (U.K.)
- Baxter (Germany)
- Aspen Holdings (South Africa)
- DAIICHI SANKYO COMPANY,LIMITED (Japan)
- Genentech, Inc. (U.S.)
- Lupin (India)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-